Shaker is one of six receiving an individual award, which recognizes people, organizations and products bringing AI to life and applying it to solve real problems
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Technology Development Board supports commercialisation of Metal Injection Molding of implants
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Dupixent peak sales ambition raised to more than €13 billion
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
Subscribe To Our Newsletter & Stay Updated
